Cryo-Cell International Q3 2026 Earnings Results & Report

Cryo-Cell International EPS Results

• Actual EPS: $0.16
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 4 of last 4 quarters

Cryo-Cell International Revenue Results

• Actual Revenue: $7.82 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cryo-Cell International (NYSEAMERICAN:CCEL), Inc. is a biotechnology company that provides private stem cell banking and related biorepository services. The company collects, processes and cryogenically stores biological materials obtained primarily from umbilical cord blood and cord tissue, which may be preserved for potential future medical use by the donor or family members.

Its services generally include the coordination of collection kits and medical collection procedures, laboratory processing, testing and long-term storage. Cryo-Cell has also offered preservation programs involving menstrual stem cells and other cellular materials, expanding its services beyond traditional cord blood banking.

Founded in 1989, Cryo-Cell International is headquartered in Oldsmar, Florida. The company serves customers in the United States and has developed international relationships and licensing or affiliate arrangements to provide cord blood and tissue banking services in selected markets outside the United States.